Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
Balkan, İlker İnanç
Altay, Fatma Aybala
Çelik, Aygül Dogan
Engin, Derya Öztürk
Hatipoğlu, Çiğdem Ataman
Karahocagil, Mustafa Kasım
Ulu Kılıç, Aysegül
MetadataShow full item record
CitationBatirel, A., Balkan, İ. İ., Karabay, O., Ağalar, C., Akalın, Ş., Alıcı, Ö. ... Yılmaz, H. (2014). Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. European Journal of Clinical Microbiology & Infectious Diseases, 33(8), 1311-1322. https://dx.doi.org/10.1007/s10096-014-2070-6
The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality.
SourceEuropean Journal of Clinical Microbiology & Infectious Diseases
Showing items related by title, author, creator and subject.
Efficacy of colistin and non-colistin monotherapies in multi-drug resistant acinetobacter baumannii bacteremia/sepsis Karabay, Oğuz; Batırel, Ayşe; Balkan, İlker İnanç; Ağalar, Canan; Akalın, Şerife; Alıcı, Özlem; Alp, Emine; Aybala Alta, Fatma; Altın, Nilgün; Arslan, Ferhat; Aslan, Turan; Bekiroğlu, Nural; Cesur, Salim; Doğan Çelik, Aygül; Doğan, Mustafa; Durdu, Bülent; Duygu, Fazilet; Engin, Aynur; Öztürk Engin, Derya; Gönen, İbak; Güçlü, Ertuğrul; Güven, Tümer; Ataman Hatipoğlu, Çiğdem; Hoşoğlu, Salih; Karahocagil, Mustafa; Ulu Kılıç, Ayşegül; Örmen, Bahar; Özdemir, Davut; Özer, Serdal; Öztoprak, Nefise; Sezak, Nurbanu; Turhan, Vedat; Türker, Nesrin; Yılmaz, Hava (Acta Medica Mediterranea, 2014)Objective: This retrospective study aimed to investigate the efficacies of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia (MDR-AB). Materials and methods: Cases with ...
Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: A Multicenter retrospective analysis İnanç Balkan, İlker; Batırel, Ayşe; Karabay, Oğuz; Aǧalar, Canan; Akalın, Şerife; Alıcı, Özlem; Alp, Emine; Altay, Fatma Aybala; Altın, Nilgün; Arslan, Ferhat; Aslan, Turan; Bekiroğlu, Nural; Cesur, Salih; Doǧan Çelik, Aygül; Doǧan, Mustafa; Durdu, Bülent; Duygu, Fazilet; Engin, Aynur; Öztürk Engin, Derya; Gönen, İbak; Güçlü, Ertuğrul; Güven, Tümer; Hatipoǧlu, Çiǧdem; Hoşoǧlu, Salih; Karahocagil, Mustafa Kasım; Ulu Kılıç, Ayşegül; Örmen, Bahar; Özdemir, Davut; Özer, Serdar; Öztoprak, Nefise; Sezak, Nur Banu; Turhan, Vedat; Türker, Nesrin; Yılmaz, Hava (Medknow Publications, 2015)Objectives: To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A) . Materials and ...
Resistance to colistin associated with a single amino acid change in protein PmrB among Klebsiella pneumoniae isolates of worldwide origin Jayol, Aurelie; Poirel, Laurent; Brink, Adrian; Villegas, Maria-Virginia; Yılmaz, Mesut; Nordmann, Patrice (American Society for Microbiology, 2014)A series of colistin-resistant Klebsiella pneumoniae isolates recovered from different countries was investigated in order to evaluate the involvement of the PmrA/PmrB two-component system in this resistance. Six isolates ...